The drug landscape in India is increasingly characterized by a pattern toward market concentration, with a handful of prominent companies wielding significant power. These sector giants, often bolstered by long-standing distribution networks and robust brand recognition, present a difficult picture for competition and accessible healthcare. While s

The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces rising concerns about monopolies. A few dominant players control a significant percentage of the market, potentially hampering competition and driving up prices for consumers. This concern raises worries about the long-term impact on patient access to affo